Poxel expects 2026 TWYMEEG Japan royalties to rise to 12% on Sumitomo sales forecast

Reuters2026/07/30 19:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Poxel expects to receive 12% royalties on TWYMEEG net sales in Japan during Sumitomo Pharma’s FY2026.
Sumitomo Pharma anticipates moderate double-digit TWYMEEG sales growth, forecasting net sales above JPY 10 billion.
Crossing JPY 10 billion would trigger a JPY 1 billion payment to Poxel, with proceeds earmarked to repay the bond issue.
Q2 net sales rose 32% to JPY 2.9 billion; Poxel booked EUR 1.24 million turnover, including JPY 229 million royalties at 8%.
Merck Serono receives a fixed 8% royalty on imeglimine net sales; positive net royalties go to OrbiMed debt repayment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Poxel SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260730067276) on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Poxel expects 2026 TWYMEEG Japan royalties to rise to 12% on Sumitomo sales forecast

You may also like

Crypto prices